公开(公告)号：US20190263833A1

公开(公告)日：2019-08-29

申请号：US16336934

申请日：2017-10-02

Applicant: Janssen Pharmaceutica NV

Inventor： Tongfei WU ,  Dirk BREHMER ,  Lijs BEKE ,  An BOECKX ,  Gaston Stanislas Marcella DIELS ,  Edward Charles LAWSON ,  Lieven MEERPOEL ,  Vineet PANDE ,  Marcus Cornelis Bernardus Catharina PARADÉ ,  Wim Bert Griet SCHEPENS ,  Weimei SUN ,  Johannes Wilhelmus John F. THURING ,  Marcel VIELLEVOYE

IPC: C07D519/00 ,  C07D487/04 ,  A61P35/00 ,  A61K9/00

Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

公开(公告)号：US20200289539A1

公开(公告)日：2020-09-17

申请号：US16082020

申请日：2017-02-24

Applicant: Janssen Pharmaceutica NV

Inventor： Didier Jean-Claude BERTHELOT ,  Dirk BREHMER ,  Lijs BEKE ,  An BOECKX ,  Gaston Stanislas Marcella DIELS ,  Ronaldus Arnodus Hendrika Joseph GILISSEN ,  Edward Charles LAWSON ,  Vineet PANDE ,  Marcus Cornells Bernardus Catbarina PARADE ,  Wim Bert Griet SCHEPENS ,  Brian Christopher SHOOK ,  Johannes Wilhelmus John F. THURING ,  Marcel VIELLEVOYE ,  Weimei SUN ,  Tongfei WU ,  Lieven MEERPOEL

IPC: A61K31/7076 ,  A61K31/7064 ,  A61K31/706

Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

公开(公告)号：US20190322685A1

公开(公告)日：2019-10-24

申请号：US16469174

申请日：2017-12-14

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick René ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK ,  Isabelle Noëlle Constance PILATTE

IPC: C07D495/04 ,  A61P35/02

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20200172556A1

公开(公告)日：2020-06-04

申请号：US16789707

申请日：2020-02-13

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick Rene ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK

IPC: C07D519/00 ,  A61P35/02 ,  A61P3/10

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20190218230A1

公开(公告)日：2019-07-18

申请号：US16331579

申请日：2017-09-13

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick Rene ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK

IPC: C07D519/00 ,  A61P3/10 ,  A61P35/02

CPC classification number: C07D519/00 ,  A61P3/10 ,  A61P35/02 ,  C07D519/04

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20230039917A1

公开(公告)日：2023-02-09

申请号：US17734413

申请日：2022-05-02

Applicant: Janssen Pharmaceutica NV

Inventor： Xuedong DAI ,  Olivier Alexis Georges QUEROLLE ,  Daniel Jason KROSKY ,  Wei CAI ,  Liqiang FU ,  Linglong KONG ,  Yingtao LIU ,  Zhao-Kui WAN ,  Barbara MORSCHHÄUSER GEB. HERKERT ,  Vineet PANDE ,  James Patrick EDWARDS ,  Aaron Nathaniel PATRICK ,  Patrick René ANGIBAUD ,  Virginie Sophie PONCELET

IPC: C07D495/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20200369707A1

公开(公告)日：2020-11-26

申请号：US16769793

申请日：2018-12-06

Applicant: Janssen Pharmaceutica NV

Inventor： Jonas VERHOEVEN ,  Guido Alfons F. VERNIEST ,  Johannes Wilhelmus John F. THURING ,  Tongfei WU ,  Vineet PANDE ,  Lieven MEERPOEL ,  Dirk BREHMER ,  Weimei SUN ,  Scott E. DENMARK

IPC: C07H19/167

Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

公开(公告)号：US20190211036A1

公开(公告)日：2019-07-11

申请号：US16331606

申请日：2017-09-13

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick Rene ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK ,  Isabelle Noelle Constance PILATTE

IPC: C07D519/00 ,  A61P35/02 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  A61P35/02

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.